# CJC-1295 Ipamorelin as a Growth Hormone Secretagogue: The Dual-Pathway Class > CJC-1295 Ipamorelin as a growth hormone secretagogue: how a GHRH analogue and a ghrelin-receptor agonist define two arms of the GH-secretagogue class, fully cited. Two arms of one drug class — the GHRH analogue and the ghrelin-receptor agonist — and how they compare to sermorelin and tesamorelin. ## In plain English A growth hormone secretagogue is anything that makes your own pituitary gland release more growth hormone (GH), rather than injecting GH itself. CJC-1295 Ipamorelin is two secretagogues at once, and understanding it as a growth hormone secretagogue class — not a single product — is the clearest way in. There are two main "doors" into the GH-releasing cell. One door is the GHRH receptor; CJC-1295 (and its cousins sermorelin and tesamorelin) knock on that one. The other door is the ghrelin receptor; ipamorelin knocks on that one. Drugs that use the first door are called GHRH analogues. Drugs that use the second are called GHRPs (growth-hormone-releasing peptides). The reason people combine CJC-1295 with ipamorelin is simple: open both doors at once and the cell releases more GH than either door opens alone. This page maps the class and where the close relatives — sermorelin, tesamorelin — sit within it. ## Two arms of the secretagogue class The growth hormone secretagogue class divides by receptor. The **GHRH-analogue arm** mimics growth-hormone-releasing hormone at the GHRH receptor (a Gs-coupled, cAMP-raising class-B GPCR). CJC-1295, sermorelin, and tesamorelin all belong here; they differ mainly in how long they last. The **GHRP / ghrelin-agonist arm** acts at GHS-R1a, the ghrelin receptor (Gq-coupled, calcium-raising). Ipamorelin, GHRP-6, GHRP-2, and hexarelin belong here. The two arms are pharmacologically distinct and complementary — which is precisely why the synergy literature matters. Submaximal GHRP combined with GHRH stimulated GH release synergistically in normal men, through independent mechanisms [3], and co-activating both receptors roughly doubled the cAMP signal versus GHRH alone in cell models [4]. The class-defining virtue of ipamorelin specifically is selectivity: it was the first secretagogue to release GH without raising ACTH or cortisol, even at more than 200 times its GH ED50 [2], distinguishing it from the older, less clean GHRPs. ## Ipamorelin vs sermorelin Ipamorelin vs sermorelin is a comparison across the two arms, not within one. Sermorelin is a GHRH analogue — the GHRH(1-29) fragment — so it works through the same GHRH-receptor / cAMP door as CJC-1295, with a short native-like half-life. Ipamorelin is a GHRP that works through the ghrelin-receptor / calcium door [2]. They are not interchangeable; they are complementary, which is why a GHRH analogue is often discussed alongside a GHRP rather than instead of one. No controlled head-to-head human trial directly compares ipamorelin with sermorelin, so any "which is stronger" claim is mechanistic inference, not measured fact. What the literature supports is that combining a GHRH-arm agent with a GHRP-arm agent produces supra-additive GH release [3][4] — the mechanistic argument for pairing rather than choosing. CJC-1295 differs from sermorelin chiefly by duration, which the DAC chemistry explains on the [cjc 1295 dac](/cjc-1295-dac) page. ## Ipamorelin vs tesamorelin Ipamorelin vs tesamorelin is again a cross-arm comparison. Tesamorelin is a stabilized GHRH analogue — the GHRH-receptor arm — and it is the most clinically validated GHRH analogue: a 2026 meta-analysis of 5 randomized controlled trials found significant reductions in visceral adipose tissue (−27.71 cm²) and hepatic fat (−4.28%), increased lean body mass (+1.42 kg) and IGF-1, with no serious adverse events [7]. Ipamorelin is the ghrelin-receptor arm, with efficacy data largely from rodent models and no published human pharmacokinetics [2]. So the honest comparison is asymmetric: tesamorelin has high-quality human RCT outcome data on body composition; ipamorelin does not, and the CJC-1295 + ipamorelin blend certainly does not. Tesamorelin's results are best read as read-across evidence that GHRH-arm stimulation can drive visceral- and hepatic-fat reduction — context for the GHRH half of the pairing, not a stand-in for blend data. ## Where the combination sits in the class Within the growth hormone secretagogue landscape, CJC-1295 + ipamorelin is the canonical "one from each arm" pairing: a long-acting GHRH analogue plus the cleanest selective GHRP. The design intent is to supply both a sustained GHRH background and a sharp ghrelin-driven pulse, exploiting the documented GHRH-plus-GHRP synergy [3][4]. The class as a whole is generally well tolerated in the short term, with the chief metabolic concern being increased blood glucose from decreased insulin sensitivity, and long-term cancer-incidence and mortality data still needed [6]. None of the class members discussed here is FDA-approved as marketed in research-chemical form, and all GH secretagogues are prohibited at all times in sport under the World Anti-Doping Code (Section S2). The combination inherits both the class's mechanistic promise and its unresolved long-term questions. --- A mechanism-first reading of the CJC-1295 and ipamorelin record — two receptors, two timescales, every figure logged to its study and the untested fixed blend kept in plain view; no clinic behind the console and nothing here dosed, stacked, prescribed, or sold.